Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National surgical adjuvant breast and bowel project protocol B-27

Harry D. Bear, Stewart Anderson, Roy E. Smith, Charles E. Geyer, Eleftherios P. Mamounas, Bernard Fisher, Ann M. Brown, Andre Robidoux, Richard Margolese, Morton S. Kahlenberg, Soonmyung Paik, Atilla Soran, D. Lawrence Wickerham, Norman Wolmark

Research output: Contribution to journalArticle

689 Citations (Scopus)

Abstract

Purpose: This study was designed to determine the effect of adding docetaxel (T) to preoperative doxorubicin and cyclophosphamide (AC) on breast cancer response rates and disease-free survival (DFS) and overall survival (OS). Patients and Methods: Women with operable breast cancer (N = 2,411) were randomly assigned to receive preoperative AC followed by surgery, AC followed by T and surgery, or AC followed by surgery and then T. Tamoxifen was initiated concurrently with chemotherapy. Median time on study for 2,404 patients with follow-up was 77.9 months. Results: Addition of T to AC did not significantly impact DFS or OS. There were trends toward improved DFS with addition of T. The addition of T reduced the incidence of local recurrences as first events (P = .0034). Preoperative T, but not postoperative T, significantly improved DFS in patients who had a clinical partial response after AC (hazard ratio [HR] = 0.71; 95% CI, 0.55 to 0.91; P = .007). Pathologic complete response, which was doubled by addition of preoperative T, was a significant predictor of OS regardless of treatment (HR = 0.33; 95% CI, 0.23 to 0.47; P < .0001). Pathologic nodal status after chemotherapy was a significant predictor of OS (P < .0001). Conclusion: The addition of preoperative or postoperative T after preoperative AC did not significantly affect OS, slightly improved DFS, and decreased the incidence of local recurrences. The sample size of this study was not sufficient to yield significance for the moderate DFS improvement. Concurrent use of tamoxifen may have limited the impact of adding T.

Original languageEnglish (US)
Pages (from-to)2019-2027
Number of pages9
JournalJournal of Clinical Oncology
Volume24
Issue number13
DOIs
StatePublished - May 1 2006

Fingerprint

docetaxel
Doxorubicin
Cyclophosphamide
Breast
Disease-Free Survival
Breast Neoplasms
Survival
Tamoxifen
Recurrence
Drug Therapy
Incidence
Sample Size

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer : National surgical adjuvant breast and bowel project protocol B-27. / Bear, Harry D.; Anderson, Stewart; Smith, Roy E.; Geyer, Charles E.; Mamounas, Eleftherios P.; Fisher, Bernard; Brown, Ann M.; Robidoux, Andre; Margolese, Richard; Kahlenberg, Morton S.; Paik, Soonmyung; Soran, Atilla; Wickerham, D. Lawrence; Wolmark, Norman.

In: Journal of Clinical Oncology, Vol. 24, No. 13, 01.05.2006, p. 2019-2027.

Research output: Contribution to journalArticle

Bear, HD, Anderson, S, Smith, RE, Geyer, CE, Mamounas, EP, Fisher, B, Brown, AM, Robidoux, A, Margolese, R, Kahlenberg, MS, Paik, S, Soran, A, Wickerham, DL & Wolmark, N 2006, 'Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National surgical adjuvant breast and bowel project protocol B-27', Journal of Clinical Oncology, vol. 24, no. 13, pp. 2019-2027. https://doi.org/10.1200/JCO.2005.04.1665
Bear, Harry D. ; Anderson, Stewart ; Smith, Roy E. ; Geyer, Charles E. ; Mamounas, Eleftherios P. ; Fisher, Bernard ; Brown, Ann M. ; Robidoux, Andre ; Margolese, Richard ; Kahlenberg, Morton S. ; Paik, Soonmyung ; Soran, Atilla ; Wickerham, D. Lawrence ; Wolmark, Norman. / Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer : National surgical adjuvant breast and bowel project protocol B-27. In: Journal of Clinical Oncology. 2006 ; Vol. 24, No. 13. pp. 2019-2027.
@article{421772814e124c29ab8df527dcfb74b2,
title = "Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National surgical adjuvant breast and bowel project protocol B-27",
abstract = "Purpose: This study was designed to determine the effect of adding docetaxel (T) to preoperative doxorubicin and cyclophosphamide (AC) on breast cancer response rates and disease-free survival (DFS) and overall survival (OS). Patients and Methods: Women with operable breast cancer (N = 2,411) were randomly assigned to receive preoperative AC followed by surgery, AC followed by T and surgery, or AC followed by surgery and then T. Tamoxifen was initiated concurrently with chemotherapy. Median time on study for 2,404 patients with follow-up was 77.9 months. Results: Addition of T to AC did not significantly impact DFS or OS. There were trends toward improved DFS with addition of T. The addition of T reduced the incidence of local recurrences as first events (P = .0034). Preoperative T, but not postoperative T, significantly improved DFS in patients who had a clinical partial response after AC (hazard ratio [HR] = 0.71; 95{\%} CI, 0.55 to 0.91; P = .007). Pathologic complete response, which was doubled by addition of preoperative T, was a significant predictor of OS regardless of treatment (HR = 0.33; 95{\%} CI, 0.23 to 0.47; P < .0001). Pathologic nodal status after chemotherapy was a significant predictor of OS (P < .0001). Conclusion: The addition of preoperative or postoperative T after preoperative AC did not significantly affect OS, slightly improved DFS, and decreased the incidence of local recurrences. The sample size of this study was not sufficient to yield significance for the moderate DFS improvement. Concurrent use of tamoxifen may have limited the impact of adding T.",
author = "Bear, {Harry D.} and Stewart Anderson and Smith, {Roy E.} and Geyer, {Charles E.} and Mamounas, {Eleftherios P.} and Bernard Fisher and Brown, {Ann M.} and Andre Robidoux and Richard Margolese and Kahlenberg, {Morton S.} and Soonmyung Paik and Atilla Soran and Wickerham, {D. Lawrence} and Norman Wolmark",
year = "2006",
month = "5",
day = "1",
doi = "10.1200/JCO.2005.04.1665",
language = "English (US)",
volume = "24",
pages = "2019--2027",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "13",

}

TY - JOUR

T1 - Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer

T2 - National surgical adjuvant breast and bowel project protocol B-27

AU - Bear, Harry D.

AU - Anderson, Stewart

AU - Smith, Roy E.

AU - Geyer, Charles E.

AU - Mamounas, Eleftherios P.

AU - Fisher, Bernard

AU - Brown, Ann M.

AU - Robidoux, Andre

AU - Margolese, Richard

AU - Kahlenberg, Morton S.

AU - Paik, Soonmyung

AU - Soran, Atilla

AU - Wickerham, D. Lawrence

AU - Wolmark, Norman

PY - 2006/5/1

Y1 - 2006/5/1

N2 - Purpose: This study was designed to determine the effect of adding docetaxel (T) to preoperative doxorubicin and cyclophosphamide (AC) on breast cancer response rates and disease-free survival (DFS) and overall survival (OS). Patients and Methods: Women with operable breast cancer (N = 2,411) were randomly assigned to receive preoperative AC followed by surgery, AC followed by T and surgery, or AC followed by surgery and then T. Tamoxifen was initiated concurrently with chemotherapy. Median time on study for 2,404 patients with follow-up was 77.9 months. Results: Addition of T to AC did not significantly impact DFS or OS. There were trends toward improved DFS with addition of T. The addition of T reduced the incidence of local recurrences as first events (P = .0034). Preoperative T, but not postoperative T, significantly improved DFS in patients who had a clinical partial response after AC (hazard ratio [HR] = 0.71; 95% CI, 0.55 to 0.91; P = .007). Pathologic complete response, which was doubled by addition of preoperative T, was a significant predictor of OS regardless of treatment (HR = 0.33; 95% CI, 0.23 to 0.47; P < .0001). Pathologic nodal status after chemotherapy was a significant predictor of OS (P < .0001). Conclusion: The addition of preoperative or postoperative T after preoperative AC did not significantly affect OS, slightly improved DFS, and decreased the incidence of local recurrences. The sample size of this study was not sufficient to yield significance for the moderate DFS improvement. Concurrent use of tamoxifen may have limited the impact of adding T.

AB - Purpose: This study was designed to determine the effect of adding docetaxel (T) to preoperative doxorubicin and cyclophosphamide (AC) on breast cancer response rates and disease-free survival (DFS) and overall survival (OS). Patients and Methods: Women with operable breast cancer (N = 2,411) were randomly assigned to receive preoperative AC followed by surgery, AC followed by T and surgery, or AC followed by surgery and then T. Tamoxifen was initiated concurrently with chemotherapy. Median time on study for 2,404 patients with follow-up was 77.9 months. Results: Addition of T to AC did not significantly impact DFS or OS. There were trends toward improved DFS with addition of T. The addition of T reduced the incidence of local recurrences as first events (P = .0034). Preoperative T, but not postoperative T, significantly improved DFS in patients who had a clinical partial response after AC (hazard ratio [HR] = 0.71; 95% CI, 0.55 to 0.91; P = .007). Pathologic complete response, which was doubled by addition of preoperative T, was a significant predictor of OS regardless of treatment (HR = 0.33; 95% CI, 0.23 to 0.47; P < .0001). Pathologic nodal status after chemotherapy was a significant predictor of OS (P < .0001). Conclusion: The addition of preoperative or postoperative T after preoperative AC did not significantly affect OS, slightly improved DFS, and decreased the incidence of local recurrences. The sample size of this study was not sufficient to yield significance for the moderate DFS improvement. Concurrent use of tamoxifen may have limited the impact of adding T.

UR - http://www.scopus.com/inward/record.url?scp=33646445341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646445341&partnerID=8YFLogxK

U2 - 10.1200/JCO.2005.04.1665

DO - 10.1200/JCO.2005.04.1665

M3 - Article

C2 - 16606972

AN - SCOPUS:33646445341

VL - 24

SP - 2019

EP - 2027

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 13

ER -